Biomarkers of disease progression and therapeutic response are transforming the field of neurology, enabling earlier diagnosis, improved patient stratification, and more precise evaluation of treatment efficacy.
The NULISA CNS Disease Panels enable robust profiling of the most important biomarkers of neurodegenerative disease progression and therapeutic response at the lowest limit of detection, in both plasma and CSF.
Providing best-in-class sensitivity and robust, multiplexed analysis of 120+ neuro-specific and inflammatory proteins associated with neurodegenerative disorders.
This Nature Communications paper demonstrates the exceptional performance of the NUcleic acid Linked Immuno-Sandwich Assay (NULISA™) in detecting biologically important low-abundance biomarkers.
"*" indicates required fields
